The Race to Cure Untreatable Cancers, Ken Galbraith, Chair and CEO, Zymeworks

Biotech 2050 Podcast

Synopsis: In the recent episode of Biotech2050, Ken Galbraith, CEO of Zymeworks, shares profound insights into the biotech industry, leadership, and the complexities of developing innovative treatments for challenging cancers. Galbraith's accidental entry into biotech in 1987, despite lacking prior experience, led to his pivotal role in establishing a successful biotech company in Canada, shaping the industry significantly. Throughout the conversation, he emphasizes the critical elements of leadership, continuous learning, and the relentless pursuit of groundbreaking science. Galbraith's focus on addressing unmet medical needs and navigating the dynamic biotech landscape offers valuable lessons for current and aspiring biotech leaders. Furthermore, his involvement in developing innovative biologic structures for difficult-to-treat cancers, exemplified by Zymeworks' mission, underscores the episode's relevance for biotech professionals seeking insights into leadership, growth, and pioneering solutions for challenging medical conditions. Galbraith's wealth of experience and strategic approach provide a compelling narrative that makes this episode an invaluable resource for understanding the keys to success in the dynamic and impactful field of biotechnology. Biography: Mr. Galbraith has served as Zymeworks’ Chair & CEO since January 2022. Mr. Galbraith has over 35 years’ experience in biotechnology and venture capital having acted as an executive, director, investor as well as an advisor to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors across North America and the UK in the growth of both private and public companies from an early-stage through regulatory approval and commercialization. Ken has worked with many biotechnology companies including: Liminal BioSciences Inc., Macrogenics, AnorMED, Alder Pharmaceuticals, Celator Pharmaceuticals, Novadaq, Profound Medical, Fairhaven Pharmaceuticals, Tekmira, Angiotech, Aquinox, and Xenon Pharmaceuticals among others. Mr. Galbraith currently serves on the board of directors of Profound Medical He earned a Bachelor of Commerce (Honors) degree from the University of British Columbia in 1985.